Transthyretin Amyloidosis (ATTR)

European Society of Cardiology (ESC) 2025

Congress Details

calander29 August - 1 September 2025 | SPAIN

locationMadrid, Spain

The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content related to vutrisiran. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].

Image
Oral

Congress Materials

Image
icon Presentation Type
Poster
Image
location icon Location
Madrid, Spain
Image
icon Title
Vutrisiran Reduces Days Lost to Death andor Hospitalization Versus Placebo in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial
Image
icon Presentation Type
Presentation
Image
location icon Location
Madrid, Spain
Image
icon Title
HELIOS-B 12-Month Results from the Open-Label Extension Period of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Preparation Date
March 2026
Job Code
MB-UK-00118